
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen is expected to have a strong year ahead with the launch of new biomarkers, improved reimbursement and billing initiatives, and sustainable growth in test ASPs. This, coupled with the company's recent positive revenue and volume performance, makes us optimistic about its future growth potential. Furthermore, Exagen's recent expansion of its sales force and plans to launch one new product per year position the company for continued success in the market.
Bears say
Exagen is a medical technology company focused on offering proprietary diagnostic tests to a targeted population of rheumatologists, with a strategy to become a value-added partner in the diagnosis, monitoring, and treatment of autoimmune diseases. Despite a large US addressable market and significant unmet need, Exagen faces the challenge of a small target physician population and potential competition in the future. Its financial success will depend on the successful development of new tests and establishing partnerships with its physician customers.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares